A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.

Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.

The treatment can offer patients a more potent, cost-effective alternative providing long-lasting relief compared to current pain regimens.

Regularly going to the dentist, researchers added, may reduce cardiovascular risks by a significant margin.

These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care. 

No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?

Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.